Almac launches next generation sequencing data analysis

Wednesday, February 1, 2012 03:28 PM

Almac Group’s diagnostics business unit has launched its advanced version of next generation sequencing (NGS) data analysis services.  These latest enhancements to Almac’s service portfolio include a comprehensive range of NGS solutions from professional study design to sample processing and expert data analysis for DNA and RNA samples. 

"By expanding our services to include this range of DNA and RNA-sequencing analysis, we are empowering our customers with the most cutting edge technologies, opening new avenues within their research and boosting the potential for advancement of human health in a variety of disease settings,” said Michael Sloan, vice president of business development for Almac.

The enhanced services are customizable and are available on a standalone basis or in combination with Almac’s established bioinformatics offerings in the areas of biomarker and drug discovery, biological analysis and development and diagnostic product development.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs